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allelic Polymorphism Determines 
surface expression or intracellular 
retention of the human nK cell 
receptor Kir2Dl5a (cD158f)
Elisa Cisneros, Ernesto Estefanía and Carlos Vilches*
Immunogenetics and Histocompatibility, Instituto de Investigación Sanitaria Puerta de Hierro, Madrid, Spain
KIR2DL5 (CD158f) is the most recently identified inhibitory member of human killer-cell 
Ig-like receptors (KIRs), which enable NK cells to sense self-HLA. Unlike KIR2DL1–3, 
recognizing HLA-C allotypes through Ig-like domains of the D1–D2 type, KIR2DL5 shares 
a D0–D2 configuration with KIR2DL4, and its ligands have not been identified. KIR2DL5 
is encoded by two paralogous genes displaying copy number variation and allelic poly-
morphism—KIR2DL5A and KIR2DL5B. UP-R1 mAb, raised against the common allele 
KIR2DL5A*001, enables specific KIR2DL5 detection. However, not every KIR2DL5+ indi-
vidual has NK cells staining with UP-R1, discrepancy explained in part by epigenetically 
silent KIR2DL5B alleles with a distinctive substitution in a promoter RUNX-binding site. 
Furthermore, we show here that the transcribed allele KIR2DL5A*005, second most 
common of its locus, fails to confer NK cells UP-R1 reactivity, phenotype explained by 
inefficacious transport of its product to the cell surface. Two amino acid substitutions dis-
tinguish the KIR2DL5A*005 and *001 coding regions. Western blot, flow cytometry, and 
confocal microscopy analyses of cells transfected with tagged constructs demonstrate 
that a serine substitution for glycine-174, conserved in most KIR, is mainly responsible 
for KIR2DL5A*005 intracellular retention, and it also affects mAb recognition. In contrast, 
substitution of aspartate for asparagine 152 has only a minor effect on surface expres-
sion, despite destroying an otherwise conserved N-glycosylation site. Our results help to 
explain the variable expression profile of KIR2DL5+ subjects and indicate that functional 
polymorphisms in both its promoter and its coding regions are critical for understanding 
the KIR2DL5 role in immunity and its importance for human health.
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inTrODUcTiOn
Several inhibitory members of the human killer-cell Ig-like receptors (KIRs) family recognize allo-
types of classical HLA class I molecules, and they enable NK cells to monitor, through the missing-self 
mechanism, selective subversion of antigen presentation in infected and tumor cells (1, 2). Besides, 
other KIRs have less well-defined functions in immunity (3). Among these is KIR2DL5 (CD158f), 
Abbreviations: HEK, human embryonic kidney; KIR, killer-cell Ig-like receptor.
TaBle 1 | common dimorphisms of the KIR2DL5 coding and promoter 
regions.
representative alleles
locus Promoter nucleotide -97 asn152-gly174 asp152-ser174
KIR2DL5A G *001 *005
KIR2DL5B A/Ga *006 *002
Guanidine at nucleotide -97 correlates with clonal transcription; adenosine with 
complete silencing; Asn152-Gly174 and Asp152-Ser174 with cell surface and 
intracellular expression, respectively.
aEach of KIR2DL5B*006 and *002 comprises multiple alleles coding for identical 
polypeptides, but differing from each other by changes in nucleotide -97 (besides other 
non-coding or synonymous substitutions) (13).
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which is identified in surveys of the human genome years after the 
other KIR (4, 5). Like the divergent KIR 2DL4, 2DL5 has Ig-like 
domains homologous to the D0 and D2 of three-domain KIR and 
is conserved in several hominoid species. But unlike KIR 2DL4, 
2DL5 shares with HLA-C-specific KIR 2DL1–3 (i.e., those with 
D1–D2 domains) a clearly inhibitory capacity and clonal expres-
sion on NK cells and T-lymphocytes (6). The ligand recognized 
by KIR2DL5 remains, however, elusive.
KIR2DL5 has a complex genetics due to copy number vari-
ation and allelic polymorphism (7). It is encoded in the human 
genome by two closely related genes—KIR2DL5A in the telomeric 
segment of KIR haplotypes and KIR2DL5B in the centromeric 
interval (8, 9). Each of these loci is present or absent in differ-
ent common haplotypes. Moreover, KIR2DL5A has undergone 
further duplication in some rare haplotypes (10–12). KIR2DL5A 
and B are represented by 15 and 28 alleles, respectively, in the 
Immuno Polymorphism Database release 2.6.0 (5 and 13 alleles, 
without taking into account non-coding polymorphisms) (13). 
KIR2DL5A is most commonly represented by allele 2DL5A*001, 
followed in frequency by 2DL5A*005, whereas the centromeric 
locus is usually represented by allele 2DL5B*002 and also by 
2DL5B*006 in Black populations [Ref. (11, 14–17) and our own 
unpublished data].
Allelic polymorphism affects the coding and the non-coding 
regions of KIR2DL5 (7, 13). Of particular functional relevance is 
one polymorphic G > A substitution at nucleotide 97 before the 
initiation codon that destroys a RUNX-binding site conserved 
in the proximal promoter of most KIR. Such change correlates 
exactly with complete epigenetic silencing of the common alleles 
of KIR2DL5B and the KIR3DP1 pseudogene, while all known 
KIR2DL5A and a few KIR2DL5B and KIR3DP1 alleles have intact 
RUNX-binding sites and are clonally transcribed (8, 14, 18–20).
Also of interest are two linked dimorphisms in the exon cod-
ing for the membrane-proximal D2 Ig-like domain (codons 152 
and 174), since they sort all alleles of both the centromeric and 
the telomeric KIR2DL5 loci into two mutually exclusive groups 
(Table  1). Asparagine and glycine are seen in the common 
2DL5A*001 allele, in 2DL5B*006, and in other less-common 
alleles of both loci, besides being conserved in virtually all KIR, 
while 2DL5A*005 on the telomeric side, the dominant centro-
meric allele 2DL5B*002 and others encode aspartate and serine 
at those positions (7). No KIR2DL5 allele with a mixed motif has 
been described.
Generation of a specific monoclonal antibody, UP-R1, enabled 
us to substantiate KIR2DL5 protein expression on NK cells and 
to characterize its biochemical and functional features. However, 
characterization was limited to NK cells expressing the dominant 
allele KIR2DL5A*001, against which the mAb was raised (6). 
Some discrepancies between genotyping and flow cytometry 
studies were subsequently observed, and they suggested that 
the aforementioned polymorphisms in the KIR2DL5 primary 
structure might somehow affect protein expression or recogni-
tion by UP-R1, still the only available mAb specific for KIR2DL5. 
In this study, we build on those observations and demonstrate 
that phenotypic, functional, and structural diversity of KIR2DL5 
depends, not only on copy number variation and variable tran-
scription but also on allelic polymorphism targeting KIR2DL5 to 
either NK-cell surface expression or intracellular retention.
MaTerials anD MeThODs
Kir2Dl5–Flag constructs, cell lines 
culture, and Transfection
A KIR2DL5A*001 cDNA clone with a FLAG epitope 
(DYKDDDDK) inserted between the leader peptide and the 
D0 Ig-like domain (6) was used to generate, by site-directed 
mutagenesis, three additional constructs bearing each of the 
missense mutations that distinguish the KIR2DL5A*001 and 
*005 primary structures—constructs N152D (152 AAT → GAT, 
asparagine to aspartate), G174S (GGC → AGC, glycine to serine), 
and KIR2DL5A*005 (both changes). Plasmids were purified using 
the EndoFree Plasmid Maxi and Midi Kits (Qiagen, Valencia, 
CA, USA) and sequenced with the universal primer SP6 and the 
internal primer R5e61 (5′-gttttggagcttggttcag-3′). Only error-free 
clones were used for transfection. Transfection experiments were 
replicated using up to five different plasmid batches per construct 
to control for random variations in expression attributable to 
DNA quality.
Human embryonic kidney (HEK)-293T cells were cultured in 
DMEM (Corning Inc., Corning, NY, USA) supplemented with 
2  mM l-glutamine, 1% penicillin–streptomycin, and 10% FBS 
(Gibco Life Technologies, Carlsbad, CA, USA), and transiently 
co-transfected by the calcium phosphate method with 5 µg of each 
KIR2DL5 construct and 0.1  µg of pEGFP-N1 vector (Clontech 
Laboratories, Palo Alto, CA, USA). Jurkat cells were cultured 
in RPMI-1640 Glutamax (Sigma-Aldrich, St. Louis, MO, USA) 
supplemented with 10% FBS and 1% penicillin–streptomycin, 
and transiently transfected with 2 µg of each KIR2DL5 construct 
along with 0.1 µg of pEGFP-N1, using Solution V and the X-01 
program of a Nucleofector I apparatus (Amaxa Biosystems, 
Cologne, Germany).
Western Blot
Forty-eight hours after transfection, 2  ×  105 HEK-293T cells 
were lysed in 1% Non-idet P-40 Substitute (Sigma-Aldrich, St. 
Louis, MO, USA), 20 mM Tris–HCl, pH 8, 137 mM NaCl, 2 mM 
Na2EDTA lysis buffer containing 1% protease inhibitor cocktail 
(Roche Diagnostics GmbH, Mannheim, Germany). Proteins 
were reduced and denatured in 5× Laemmli buffer, run in 10% 
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SDS-PAGE, and blotted to nitrocellulose membranes (iBlot Gel 
Transfer Stacks Nitrocellulose, Mini, Novex Life Technologies, 
Grand Island, NY, USA), which were treated for 1 h with blocking 
buffer (Li-Cor Bioscience, Lincoln, NE, USA). KIR2DL5–FLAG 
protein bands were detected with 1:1,000 dilution of anti-FLAG 
mAb M2 (Sigma-Aldrich, St. Louis, MO, USA), and 1:5,000 sec-
ondary antibody directed against mouse IgG (IRDye800, Li-Cor 
Bioscience). Beta-actin was detected, as a positive control, with 
1:2,000 rabbit anti-human β-actin antibody (Abcam, Cambridge, 
UK) and the secondary reagent IRDye700 (Li-Cor Bioscience). 
Signals were detected with the Odyssey Infrared Imaging System 
(Li-Cor Bioscience). For N-deglycosylation, 400 µg of total cell 
lysates were denatured for 10 min at 100°C and treated with 2.5 U 
of Peptide-N-Glycosidase F (PNGase F, New England Biolabs, 
Ipswich, MA, USA) for 5 h at 37°C before Western blotting.
Flow cytometry
PBMCs or IL-2-expanded NK cells from healthy donors of known 
KIR genotype were incubated at 4°C with the following antibod-
ies: APC anti-CD56 (eBioscience, Inc., San Diego, CA, USA), PE/
Cy7 anti-CD3 (Biolegend, San Diego, CA, USA), and either PE 
anti-KIR2DL5 (UP-R1, Biolegend) or PE anti-KIR2DL2/L3/S2 
(DX27, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). 
Isotype-matched negative controls were PE IgG1 (clone MOPC-
21, Sigma-Aldrich) and PE IgG2a (clone S43.10, Miltenyi). Flow 
cytometry analysis was performed in MACSQuant Analyzer 
(Miltenyi) using MACSQuantify software. Percentages of 
KIR2DL5-positive cells were determined after gating on the 
CD3−CD56+ NK-cell population. The genotype of each donor 
was assessed using previously published polymerase chain 
reaction primers (14) targeting specific polymorphisms in the 
KIR2DL5 coding and promoter regions; the latter primers also 
enabled to rule out potential confounding presence of transcribed 
KIR2DL5B alleles. This study was carried out in accordance with 
the recommendations of the Ethical Committee of Clinical 
Research of Instituto de Investigación Sanitaria Puerta de Hierro, 
which approved the protocol (270910-258). All participating 
volunteers provided written informed consent in accordance 
with the Declaration of Helsinki.
Primary mAbs used for flow cytometry of KIR2DL5-
transfectants were anti-FLAG mAb M2 (Sigma-Aldrich), 
KIR2DL5-specific mAb UP-R1 (6), and mouse IgG1 
isotype-matched negative control MOPC-21 (Sigma-Aldrich). 
PE-conjugated goat anti-mouse IgG +  IgM, F(ab′)2 fragments 
(Jackson ImmunoResearch, West Grove, PA, USA) were used as 
secondary Ab. Jurkat and HEK-293T cells were stained 24 and 
48 h post-transfection, respectively, and transient surface expres-
sion of KIR2DL5–FLAG was determined in Epics XL (Coulter 
Electronics, Hialeah, FL, USA) or MACSQuant (Miltenyi) flow 
cytometers, using Expo32 and MACSQuantify software, respec-
tively. EGFP-positive cells ranged ~8–12% (Jurkat) and 30–40% 
(HEK-293T). Mean fluorescence intensities (MFIs) of different 
KIR2DL5 constructs, calculated after gating on EGFP+ cells, were 
compared using the paired Student’s t-test. To assess the effect 
of KIR2DL5 polymorphisms on recognition by mAb UP-R1, we 
calculated in each experiment the ratio of the MFIs obtained with 
KIR2DL5A*001 and each transfectant using M2 (anti-FLAG) and 
UP-R1, and ratios obtained for each mAb were compared using 
the non-parametric Wilcoxon signed-rank test.
confocal Microscopy
Forty-eight hours after transfection, HEK-293T cells were stained 
with anti-FLAG M2 mAb, fixed in PBS with 4% paraformalde-
hyde, and incubated with Alexa546-conjugated anti-mouse IgG 
(Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) to 
detect KIR2DL5–FLAG molecules on the surface. Then, cells 
were treated with 0.3% Triton X-100, and re-incubated with anti-
FLAG M2 mAb, followed by Alexa448-labeled anti-mouse IgG 
(Invitrogen), to detect intracellular KIR2DL5 molecules. After 
this staining strategy, based on Ref. (21), cells were visualized 
on poly-l-lysine-coated glass-bottom dishes on a confocal laser-
scanning microscope (TCS SP5, Leica Microsystems CMS GmbH, 
Mannheim, Germany) using Argon (488 nm) and Helium-Neon 
(543 nm) lasers and a 20×/0.5 lens. Images were acquired using 
the LAS AF SP5 software (Leica).
Kir2Dl5a structure Model
We based on the KIR2DL1 X-ray structure (22) (PDB accession 
code: 1NKR) to predict the structures of the D2 Ig-like domains of 
KIR2DL5A*001 and *005, using the SWISS-MODEL automated 
protein structure homology-modeling system (23), accessible via 
the ExPASy web server.1 Quality of each model was assessed with 
the QMEAN Z-score (24), which describes the likelihood that 
a model quality is comparable to high-resolution experimental 
structures.2 Structures were visualized and edited using the 
PyMOL Molecular Graphics System (version 1.7.4, Schrödinger, 
LLC).
resUlTs
allelic Polymorphism affects Kir2Dl5a 
Detection on the nK-cell surface by Flow 
cytometry
Flow cytometry assays of PBMCs from donors with a 
KIR2DL5A*001 allele identify discrete subpopulations of NK 
cells reacting with the only available anti-KIR2DL5 mAb, UP-R1 
(average of positive NK cells in 11 donors ± SD: 5.18 ± 2.15%; 
range: 1.71–7.89%), consistently with the clonal expression 
pattern reported for the receptor (4, 6). In contrast, much 
fewer UP-R1-positive NK cells are seen in donors carrying 
allele KIR2DL5A*005 (0.50 ± 0.24%; range: 0.23–0.93%; n = 9; 
p =  0.0001), their proportions being not significantly different 
from the background seen in donors lacking a transcribed 
KIR2DL5 gene (0.33 ±  0.20%; range: 0.15–0.78%; n =  11). In 
fact, the flow cytometry plots of donors pertaining to the latter 
two categories are hardly distinguishable on an individual basis 
(Figure 1), indicating that NK cells of KIR2DL5A*005 subjects 
are, for some reason, unreactive with UP-R1 in these assays.
KIR2DL5A*001-positive NK cells expanded in vitro express 
higher levels of the receptor on the surface than resting cells, 
1 http://swissmodel.expasy.org/.
2 https://swissmodel.expasy.org/qmean/cgi/index.cgi?page=help.
FigUre 1 | Flow cytometry profiles of nK cells from donors with different KIR2DL5A genotypes. Unmanipulated NK cells from peripheral blood of three 
donors expressing KIR2DL5A*001 (left, positive control), three carrying KIR2DL5A*005 (middle), and three lacking a transcribed KIR2DL5A or KIR2DL5B gene  
(right, negative control).
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FigUre 2 | nK cells expanded in vitro with il-2, isolated from three donors, each of them representing a different KIR2DL5A genotype. MOPC21 
(IgG1) and S43.10 (IgG2) are isotype-matched negative controls for the anti-KIR2DL5 (UP-R1) and anti-KIR2DL2/L3/S2 (DX27) mAbs.
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as it happens with other KIR (Figure 2). In contrast, NK cells 
expanded from individuals carrying KIR2DL5A*005 appear 
to upregulate no product detectable with UP-R1, remaining 
indistinguishable from those of a KIR2DL5A-negative donor 
(Figure 2). This argues against the possibility of a KIR2DL5A*005 
product being expressed at low levels on the surface of freshly 
isolated NK cells. Given that KIR2DL5A*005 mRNA is as readily 
detected as that of the common allele KIR2DL5A*001 (14), these 
results suggest that the putative KIR2DL5A*005 product is not 
transported to the cell surface or fails to react with mAb UP-R1.
Predictive analysis of Posttranslational 
Modifications, subcellular location, and 
Folding Motifs in Kir2Dl5a alleles
Because of the crucial role of protein posttranslational modifica-
tions on several cellular processes, including maturation and 
protein location, we analyzed whether potential KIR2DL5A 
posttranslational processing could be predictably affected by its 
allelic polymorphism. The two substitutions that distinguish the 
primary structures of KIR2DL5A*001 and *005 are located in 
the D2 Ig-like domain and involve amino acids with side chains 
susceptible to glycosylation—asparagine/aspartate-152 and gly-
cine/serine-174. Therefore, we performed a predictive search of 
possible O- and N-glycosylation motifs in the sequences of their 
D2 domains. None of the predicted O-glycosylation sites involves 
KIR2DL5 polymorphic positions (not shown). In contrast, substi-
tution of asparagine-152 by aspartate in KIR2DL5A*005 destroys 
an N-glycosylation site (Figure  3) highly conserved in all KIR 
(25), whose loss might affect KIR2DL5A*005 surface expression.
We also explored possible presence in the KIR2DL5A*005 pri-
mary structure of sequence motifs that could affect its subcellular 
location or folding. However, we found no signals for endoplasmic 
reticulum (ER) retention, such as di-basic (i.e., arginine/lysine) 
FigUre 3 | comparison of the primary structures of the KIR2DL5A*001 and *005 D2 ig-like domains, along with those of KIR2DL1 alleles *001 and 
*014, and KIR2DL4*001. Arrows mark KIR2DL5A polymorphic positions 152 and 174, and Phe-129, predictably confronted to Gly/Ser-174 in the receptor 
architecture. Other residues mentioned in the text are underlined. Amino acid numbering is based on the mature KIR2DL5A polypeptide (the KIR2DL1 N-terminal 
Ig-like domain, not represented, is five amino acids longer than those of killer-cell Ig-like receptors 2DL4 and 2DL5).
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motifs, or variants of an H/KDEL sequence seen in ER-resident 
proteins (26). Furthermore, KIR2DL5A*005, like allele *001, has 
intact WSXPS motifs in each of its Ig-like domains, mutations of 
which have been reported to hamper correct folding and surface 
expression of the KIR3DL1*004 allele (27), as well as cytokine 
receptors (28).
allele Kir2Dl5a*005 is Weakly expressed 
on the surface of Transfected cells and is 
Poorly recognized by Kir2Dl5-specific 
mab UP-r1
To reliably track the expression of KIR2DL5A*001 and *005, we 
tagged cDNA constructs of these alleles with a FLAG epitope 
which should enable us to detect their products independently 
of UP-R1 recognition. Such constructs were transfected into 
HEK-293T cells, and expression was verified by western blot 
with an anti-FLAG mAb. As shown in Figure 4A, specific bands 
of 50–60 kDa were seen in both KIR2DL5A*001 and *005-trans-
fected cells, in comparison with mock-transfected HEK-293T. 
Differences in the relative mobility of KIR2DL5A*001 and *005 
were observed, and they are attributable to their differential 
N-glycosylation, since they disappear after treatment of the 
cell lysates with PNGase F (Figure  4B). Also, due to variable 
transfection efficacy, the relative amounts of each synthesized 
protein varied between experiments (e.g., experiments 1 and 2 
of Figure 4A). To compensate for such variations, transfections 
were replicated six times using different plasmid batches, EGFP 
was co-transfected in all experiments, and KIR2DL5 expression 
was evaluated on EGFP+ cells.
Flow cytometry analysis of KIR2DL5A-transfected HEK-293T 
cells with anti-FLAG mAb revealed discrete subpopulations of cells 
showing specific surface expression of both KIR2DL5A*001 and 
*005 (Figures 5A,B). Density of the former molecule was, how-
ever, consistently and significantly higher than that of the minor 
allele KIR2DL5A*005 (average MFI of six experiments ±  SD: 
38 ±  11 vs. 9 ±  8; p =  0.0004). Similarly, flow cytometry with 
the KIR2DL5-specific mAb UP-R1 showed that KIR2DL5A*001-
transfected cells are stained more intensely than those expressing 
KIR2DL5A*005 (MFI 47 ± 16 vs. 4 ± 6; p = 0.0001, Figures 5C,D). 
These results roughly replicate the observed natural behavior 
of these alleles, except for the fact that KIR2DL5A*005 is only 
detectable on transfected cells. Furthermore, comparison of the 
staining profiles obtained with anti-FLAG M2 and anti-KIR2DL5 
UP-R1 mAbs showed that, despite following similar trends, dif-
ferences in apparent expression levels of KIR2DL5A*001 and 
*005 were somewhat more pronounced when cells were stained 
with UP-R1 mAb (Figure  5). For instance, the MFI values of 
KIR2DL5*001 cells were 5.1- to 75.0-fold higher than those of 
*005 ones when measured with UP-R1, but only 2.0- to 21.6-fold 
higher when assessed with the anti-FLAG mAb, the difference 
being statistically significant (p < 0.05) and consistently seen in 
every experiment. This behavior suggests that KIR2DL5A*005 
detection by UP-R1 is limited, not only by lower expression of 
the molecule but also by poorer recognition by the antibody.
Differential contribution of the g174s and 
n152D Polymorphisms to the 
Kir2Dl5a*005 Phenotype
To assess the relative contribution of the KIR2DL5A*005 
polymorphisms to reduced surface expression and UP-R1 mAb 
recognition of this allele, we introduced separately the G174S 
and N152D mutations into the KIR2DL5A*001 coding region, 
and analyzed expression on transfected HEK-293T cells as above, 
using anti-FLAG and anti-KIR2DL5 mAbs.
Examination of the mutants flow cytometry profiles with the 
anti-FLAG antibody (Figures  5A,B) showed that substitution 
of aspartate for asparagine-152 induced only a modest effect 
on KIR2DL5A expression levels (MFI: 26  ±  11 vs. 38  ±  11 
in KIR2DL5A*001, p  =  0.0695). In contrast, the serine for 
glycine-174 mutant displayed a significant reduction in surface 
expression in comparison with the wild-type allele (MFI: 18 ± 10 
vs. 38 ± 11, p = 0.0013). Western blot analyses of the two mutants 
revealed comparable levels of KIR2DL5 protein synthesis (not 
shown).
Analysis of expression with the KIR2DL5-specific mAb UP-R1 
replicated the results obtained with the anti-FLAG antibody, 
except for the facts that both mutants differed significantly from 
KIR2DL5A*001 (Figure 5D); and that, as it happened in the com-
parison of KIR2DL5A*001 and *005, the decrease in recognition 
of the G174S mutant was more pronounced with UP-R1 than with 
the anti-FLAG antibody (2DL5A*001/G174S MFI ratios: UP-R1, 
2.7–29.5; anti-FLAG, 1.4–4.6, p < 0.05). In fact, G174S mutants 
showed an average MFI similar to that of the low-expressed allele 
KIR2DL5A*005 (8 ±  11 vs. 4 ±  6), supporting that serine-174 
hampers recognition by the KIR2DL5-specific antibody besides 
reducing expression levels.
FigUre 4 | Western blot analysis of Kir2Dl5a expression in 
transfected human embryonic kidney (heK)-293T cells. (a) KIR2DL5A 
was immunoprecipitated from lysates of HEK-293T cells expressing 
KIR2DL5A*001 or KIR2DL5A*005 using anti-FLAG mAb. Beta-actin enables 
monitoring the amount of cell lysate loaded on the gel. Two duplicate 
independent experiments are shown. (B) Cell lysates were digested with 
Peptide-N-Glycosidase F before Western blot with anti-FLAG.
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To further validate our findings, we replicated the flow cytom-
etry analysis of each KIR2DL5 construct after nucleofection into 
Jurkat, a T-cell line previously used in studies of KIR expression 
(27, 29, 30). In line with the less effective transfection of Jurkat, 
expression levels of all KIR2DL5 constructs emulated more closely 
those seen in NK cells of KIR2DL5A*001- and *005-positive 
subjects, being 2- to 10-fold lower than those obtained with 
HEK-293T cells. Despite this difference, the relative expression of 
each construct in comparison with KIR2DL5A*001, determined 
with either UP-R1 or anti-FLAG mAbs, roughly reproduced 
that previously obtained in HEK-293T cells; i.e., percentages 
of cells with appreciable receptor density on the surface were 
conspicuously lower for KIR2DL5A*005 and the G174S mutant 
than for KIR2DL5A*001, whereas the N152D mutation had only 
a minor effect on KIR2DL5 expression and recognition by UP-R1 
(Figure 6).
allele Kir2Dl5a*005 is retained 
intracellularly Due to a serine for glycine 
substitution in the D2 ig-like Domain
Our previous results show that KIR2DL5A*005 translation is 
not followed by efficacious expression on the cell surface. To 
assess whether the KIR2DL5A*005 product is retained intra-
cellularly, we performed confocal microscopy experiments of 
HEK-293T cells transfected with FLAG-tagged constructs of 
alleles KIR2DL5A*001 and *005, and with the above described 
intermediate mutants N152D and G174S.
As shown in Figure 7, remarkable differences were seen in the 
cellular distribution of the four transfected constructs, as assessed 
with an anti-FLAG mAb. In cells expressing KIR2DL5A*001 or 
the N152D mutant, fluorescence was localized on the plasma 
membrane, without appreciable intracellular staining. In contrast, 
KIR2DL5A*005, as well as mutant G174S, were predominantly 
detected inside transfected cells, despite a small amount of 
molecules colocalizing with the plasma membrane, in agreement 
with the flow cytometry results. Unfortunately, KIR2DL5-specific 
mAb UP-R1 behaved poorly after cell fixation–permeabilization, 
which precluded subsequent studies of intracellular staining 
with this mAb to track KIR2DL5A*005 localization in NK cells 
expressing naturally this molecule.
To gain insight on the mechanism by which a serine for 
glycine-174 change in the D2 Ig-like domain could hinder 
KIR2DL5A surface expression, we analyzed this substitution in 
a predicted three-dimensional model of the receptor. To that 
end, and since the crystallographic structure of KIR2DL5 has not 
yet been solved, we modeled its D2 domain on the structure of 
KIR2DL1 (31), which, among all KIR, shares with KIR2DL5 the 
highest amino acid sequence identity in that region (86.73% with 
no gaps). QMEAN6 Z-scores, estimating the absolute quality of 
the KIR2DL5*001 and *005 models, were 0.25 and −0.43 SDs, 
respectively, from the KIR2DL1 experimental structure. KIR2DL5 
residue 152 (Asn/Asp) is exposed on the protein surface (seg-
ment connecting β-strands D and E), while amino acid 174 (Gly/
Ser) is partially hidden inside the receptor architecture (strand 
F), confronted with phenylalanine-129 (loop 5, near strand C). 
Replacement of glycine-174 in the KIR2DL5A*001 model by 
serine of KIR2DL5A*005 induces displacement of phenylala-
nine-129 (Figure 8), as a consequence of the bigger size of the ser-
ine hydroxymethyl group in comparison with the hydrogen side 
chain of glycine-174. Of note, a similar displacement of KIR2DL1 
tyrosine-134 (paralogous of KIR2DL5 Phe-129, Figure 3), result-
ing in intracellular retention, has been attributed to an identical 
FigUre 5 | Flow cytometry analysis of surface Kir2Dl5a expression on transfected human embryonic kidney-293T cells, using anti-Flag (a,B) and 
anti-Kir2Dl5 mabs (c,D), after gating on egFP+ cells. Dot plots in panels (a,c) depict one representative experiment of six analyzed in graphs (B,D); different 
symbols are used in these graphs for each experiment. To compare KIR2DL5 expression levels and compensate for variations in transfection efficacy, the mean 
fluorescence intensity achieved with M2 (B) and UP-R1 (D) mAbs was measured on cells expressing EGFP, cotransfected along with KIR2DL5 in each experiment. 
*p < 0.01, **p < 0.001; ns, not significant; SS, side scatter.
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FigUre 6 | Flow cytometry analysis of surface Kir2Dl5a expression on nucleofected Jurkat cells, using anti-Flag and anti-Kir2Dl5 mabs.
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predicted reliably by genotyping the -97 A/G dimorphism of the 
KIR2DL5 promoter—only alleles with G (part of a RUNX-binding 
site) are transcribed (14). In this study, we have addressed another 
source of apparent discrepancy between KIR2DL5 phenotyping 
and basic genotyping—lack of a detectable product despite 
presence of a KIR2DL5 allele with an intact RUNX site. We have 
shown here that this situation is regularly seen in KIR2DL5A*005, 
part of the common telomeric KIR motif 3DS1-2DL5A*005-
2DS3*002-2DS1-3DL2 (7, 10, 11, 17). According to our results, 
such phenotype can be anticipated also for KIR2DL5B*0020106 
and *00202, centromeric alleles governed by predictably func-
tional promoters and encoding mature polypeptides identical to 
KIR2DL5A*005 (16).
Western blot, flow cytometry, and confocal microscopy studies 
of cells transfected with tagged KIR2DL5A constructs show exist-
ence of a KIR2DL5A*005-gene product that, in comparison with 
the common allele KIR2DL5A*001, scarcely reaches the plasma 
membrane and is mostly retained intracellularly. Comparison of 
the flow cytometry profiles of mAbs directed against the tag and 
the receptor also reveal that the only available KIR2DL5-specific 
mAb, UP-R1, binds to 2DL5A*005 with lower efficacy than to 
2DL5A*001, suggesting that its epitope is somehow altered in 
the former allele. In consequence, we cannot exclude completely 
that KIR2DL5A*005 traces reach the NK-cell surface at levels 
undetectable by the mAb, as shown for another KIR retained 
intracellularly, 3DL1*004 (30). Against this possibility is that NK 
cells expanded from KIR2DL5A*005 subjects remain negative for 
UP-R1. We have also not ruled out that intracellular KIR2DL5 
might exert some function. In this regard, 2DL4, the only other 
Gly-to-Ser substitution in allele KIR2DL1*014 residue 179 (32), 
paralogous of KIR2DL5 amino acid 174. KIR2DL5 substitutions 
G174S and N152D appear to affect no other bonds or interactions 
between surrounding amino acids, and we found no additional 
clues to the KIR2DL5A*005 behavior by modeling on KIR2DL4 
(PDB accession code 3WYR, results not shown), receptor that, in 
contrast with KIR2DL1, shares with KIR2DL5 the D0–D2 Ig-like 
domain organization, but slightly lower percentage of identity in 
the primary structure.
DiscUssiOn
The KIR2DL5 function and importance in human health are 
poorly understood. Studies on this KIR are complicated by its 
entangled genetics and expression profiles. Most conspicuous 
in this regard is frequent discrepancy between detection of the 
receptor by flow cytometry and simple forms of KIR genotyping 
that inform only of presence or absence of a KIR2DL5 gene. Such 
contradicting results (i.e., no protein detectable by flow cytom-
etry in a KIR2DL5+ individual) are partly explained by most 
KIR2DL5B alleles being epigenetically silenced, which can be 
FigUre 7 | confocal microscopy analysis of surface and intracellular 
Kir2Dl5a expression in transfected human embryonic kidney-293T 
cells, using an anti-Flag mab. Cells were stained before (left) and after 
(middle) membrane permeabilization, using secondary reagents labeled with 
different dyes in each step.
FigUre 8 | Predicted structure of the D2 ig-like domains of Kir2Dl5 
alleles *001 and *005. Insets highlight displacement of phenylalanine-129 in 
the KIR2DL5A*005 model due to a spatial constraint posed by the 
serine-174 side chain.
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KIR2DL5 is, in many aspects, an intriguing molecule. 
Contrasting with most human KIR, it is seen in several primate 
species, feature shared by KIR2DL4. But, unlike the latter KIR, 
2DL5 is not conserved in all humans; on the contrary, despite 
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In summary, we have shown that a common polymorphism 
in the KIR2DL5 coding sequence targets the encoded receptor 
for intracellular expression, which, together with variations in its 
promoter, explains all apparent discrepancies between KIR2DL5 
geno- and phenotyping. A major implication of our results is that 
analyses of NK-cell repertoire and genetic association studies 
aimed at exploring or understanding relationship of KIR2DL5 
with different health conditions will only be meaningful if its 
allelic polymorphism and different expression profiles are taken 
into account.
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